The results support those obtained in the efficacy studies conducted with another highly virulent strain isolated in France in 2020 and reaffirm the indication of YURVAC® RHD for protection against highly virulent RHDV2 strains.
Efficacy evaluation of YURVAC® RHD against a current highly virulent RHDV2 strain
Publications
Rabbits
The aim of this study was to demonstrate the efficacy of YURVAC® RHD against one recent highly virulent strain of RHDV2
Download this article
Related products
Recombinant vaccine against rabbit haemorrhagic disease (RHD) caused by the classical (RHDV) and variant (RHDV2) strains, including highly virulent strains, in an emulsion for injection.
Inactivated vaccine against the variant strain of rabbit haemorrhagic disease (RHDV-2), in injectable emulsion.
Inactivated vaccine against the variant strain of rabbit haemorrhagic disease (RHDV-2), in injectable emulsion.
Live heterologous vaccine against myxomatosis, in injectable freeze-dried tablet.
Live homologous vaccine against myxomatosis, in injectable freeze-dried tablet
Inactivated vaccine against the classic strain of rabbit haemorrhagic disease (RHDV1), in injectable emulsion
Enrofloxacin, in oral solution, animal medicine, animal medicines, medicine for rabbits, rabbit medicine, medicine for poultry
Related services
HIPRA University offers high quality training programmes in strategic areas of interest for professionals
Access an advanced diagnostic service with maximum comfort and reliability
